Chengda Bio announced that the application for registration and listing of the domestically produced pharmaceuticals of the freeze-dried rabies vaccine for human use, developed by its wholly-owned subsidiary, Benxi Subsidiary, recently received the "Acceptance Notice" from the National Medical Products Administration. The vaccine is cultured using human diploid cells as the matrix, with advanced production technology and stable quality, and has good safety and immunogenicity.
成大生物：冻干人用狂犬病疫苗申请生产药品注册获受理
Chengda Biotech: The application for the registration of the production of pharmaceuticals for lyophilized human rabies vaccine has been accepted.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.